Predictors of Immunogenic Response to the BNT162b2 mRNA COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases Treated with Rituximab

Treatment with rituximab (RTX) blunts SARS-CoV-2 vaccination-induced humoral response. We sought to identify predictors of a positive immunogenic response to the BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic diseases (AIIRD) treated with RTX (AIIRD-RTX). We analyzed 108 AI...

Descripción completa

Detalles Bibliográficos
Autores principales: Furer, Victoria, Eviatar, Tali, Zisman, Devy, Peleg, Hagit, Braun-Moscovici, Yolanda, Balbir-Gurman, Alexandra, Paran, Daphna, Levartovsky, David, Zisapel, Michael, Elalouf, Ofir, Kaufman, Ilana, Broyde, Adi, Polachek, Ari, Feld, Joy, Haddad, Amir, Gazitt, Tal, Elias, Muna, Higazi, Nizar, Kharouf, Fadi, Pel, Sara, Nevo, Sharon, Elkayam, Ori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229869/
https://www.ncbi.nlm.nih.gov/pubmed/35746508
http://dx.doi.org/10.3390/vaccines10060901

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229869/
https://www.ncbi.nlm.nih.gov/pubmed/35746508
http://dx.doi.org/10.3390/vaccines10060901

Ejemplares similares